Yes. PT-141 (bremelanotide) is a compounded prescription peptide requiring a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required before dispensing to confirm suitability, screen for cardiovascular contraindications, and establish the appropriate dosing protocol.

Nausea is the most common side effect, typically occurring within one to two hours of injection and resolving within several hours. Facial flushing, transient headache, and mild blood pressure elevation have been reported. Transient spontaneous erections have been reported in male patients as a direct effect of central MC4R activation. Hyperpigmentation of the face, gums, or breasts may occur with repeated use and should be reported to your provider. Injection site reactions including redness or mild discomfort may occur. Report any significant cardiovascular symptoms promptly.

PT-141 is not appropriate for patients with uncontrolled hypertension or significant cardiovascular disease, as transient blood pressure elevation is a known effect. Patients on antihypertensive medications require provider evaluation before initiating. It is not appropriate during pregnancy or breastfeeding. Those with a history of melanoma or dysplastic nevi should use with caution given PT-141's melanocortin activity. Patients under 18 should not use this medication.

PT-141 may transiently elevate blood pressure — patients on antihypertensive medications require coordinated provider management to avoid additive or opposing effects. Concurrent use with nitrates is not recommended due to potential cardiovascular interactions. Other melanocortin agonists should not be combined with PT-141. Patients on medications that affect dopaminergic signaling, including antidepressants or antipsychotics, should disclose these to their provider as interactions may affect both efficacy and side effect profile.

Patients with cardiovascular conditions, uncontrolled hypertension, or a history of melanoma require individualized provider evaluation before initiating PT-141. Those with significant renal or hepatic impairment require dosing review. Blood pressure monitoring during the initial treatment period is standard of care. Your provider will review your complete medical history and current medications before prescribing.